Results 61 to 70 of about 2,116 (170)

Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report

Clinical, Cosmetic and Investigational Dermatology, 2022
Eva Moennig, Stephan Traidl Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School (MHH), Hannover, GermanyCorrespondence: Eva Moennig, Division of Immunodermatology and Allergy Research ...
Moennig E, Traidl S
doaj  

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study

Acta Dermato-Venereologica
Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), for which real-world data are scarce.
Laura Calabrese, Elisa Cinotti, Martina D’Onghia, Alessandra Cartocci, Pietro Rubegni, François Maccari , Claire Boulard, Ziad Reguiai, Pierre-André Becherel, Caroline Jacobzone, Edouard Begon, Charlotte Fite, Beatrice Walls, Anne Laure Liegeon, Josiane Parier, Guillaume Chaby, Jean-Luc Perrot   +16 more
doaj   +1 more source

Association of Tralokinumab and Adalimumab: Good Tolerance and Efficacy in a Case of Severe Atopic Dermatitis and Juvenile Idiopathic Arthritis

JEADV Clinical Practice
Atopic dermatitis is a chronic inflammatory and pruritic skin disease. The combination of tralokinumab with adalimumab in the treatment of inflammatory diseases had not yet been documented.
F. Rakotonandrasana, E. Puzenat, A. Ducournau, D. Popescu   +3 more
doaj   +1 more source

Short-Term Cost per Responder of Lebrikizumab versus Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Model-Based Payer Analysis

ClinicoEconomics and Outcomes Research
Hamad AlmutlaqDepartment of Dermatology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi ArabiaCorrespondence: Hamad Almutlaq, Department of Dermatology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam ...
Almutlaq H
doaj  

Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16

Dermatology and Therapy
Introduction Investigator’s Global Assessment (IGA) of clear/almost clear (0/1) skin is a high standard to achieve after 16 weeks of treatment for patients with moderate-to-severe atopic dermatitis (AD) and does not capture clinically meaningful ...
Amy S. Paller, Andrew Blauvelt, Weily Soong, H. Chih-ho Hong, Marie L. A. Schuttelaar, Shannon K. R. Schneider, Eric L. Simpson   +6 more
doaj   +1 more source

Tralokinumab-ldrm

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Do randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary fibrosis

, 2018
Do Randomized Clinical Trials Always Provide Certain Results?
Jones, Mark G., Luca Richeldi, Mark G. Jones, Giacomo Sgalla, Sgalla, Giacomo, Richeldi, Luca   +5 more
core   +1 more source

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy

Dermatology and Therapy
Introduction A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe atopic ...
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, James Del Rosso, Linda Stein Gold, Erin Johansson, Martin Dossenbach, Gaia Gallo, Buelent Akmaz, Marta Casillas, Andrei Karlsson, Tristan Curteis, Raj Chovatiya   +19 more
doaj   +1 more source

Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis

Health Technology Assessment
Background Atopic dermatitis is a chronic relapsing inflammatory skin condition. One of the most common skin disorders in children, atopic dermatitis typically manifests before the age of 5 years, but it can develop at any age.
Steven J Edwards, Charlotta Karner, Tracey Jhita, Samantha Barton, Gemma Marceniuk, Zenas Z N Yiu, Miriam Wittmann   +6 more
doaj   +1 more source

Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective study

Tralokinumab is a novel IgG4 monoclonal antibody against interleukin-13 recently approved for moderate-to-severe atopic dermaitits (AD) in adults and adolescents.
Sood, Siddhartha
core   +1 more source